嵌合抗原受体介导的抗肿瘤细胞治疗的发展  

Progression of chimeric antigen receptor-mediated antitumor cell-based therapy

作　　者：秦浩越 言欢 张星 黄哲 陈阳倩 张聿达 向思琦 张永昌 杨农[1,2] 曾亮 QIN Haoyue;YAN Huan;ZHANG Xing;HUANG Zhe;CHEN Yangqian;ZHANG Yuda;XIANG Siqi;ZHANG Yongchang;YANG Nong;ZENG Liang(Graduate Collaborative Training Base of Hunan Cancer Hospital,Hengyang Medical School,University of South China,Hengyang,421001,Hunan,China;Department of Pulmonary and Gastrointestinal Medicine,Hunan Cancer Hospital,Changsha,410013,Hunan,China)

机构地区：[1]南华大学衡阳医学院湖南省肿瘤医院研究生协作培养基地,湖南衡阳421001 [2]湖南省肿瘤医院肺胃肠内科,湖南长沙410013

出　　处：《肿瘤药学》2024年第2期156-165,共10页Anti-Tumor Pharmacy

基　　金：湖南省科技创新计划临床医疗技术创新引导项目(2021SK51105);湖南省科技创新计划湖湘青年英才项目(2021RC3118)。

摘　　要：嵌合抗原受体(CAR)技术驱动的T细胞疗法在肿瘤治疗中展示了巨大的创新潜力,尤其在血液肿瘤方面取得了显著成果。通过精准改造患者或供体细胞,使其能够特异性识别并清除肿瘤细胞,此策略已进入临床实践的新阶段。尽管如此,CAR-T细胞疗法在实体瘤中的治疗效果尚未达到预期,并且其潜在的不良反应引起了广泛关注。随着科技的不断进步,基于CAR技术改造的多种细胞类型,如NK细胞、巨噬细胞、NKT细胞及γδT细胞等,正在被纳入肿瘤治疗研究,拓展了治疗前景。本综述深入探讨了CAR技术的最新进展及其在细胞疗法中的应用,为抗肿瘤治疗提供潜在的新思路和可能性。Chimeric antigen receptor(CAR)technology-driven T cell therapies have demonstrated great innovation potential in the treatment of tumors,with notable results especially in hematological tumors.By precisely modifying patient or donor cells to specifically recognize and remove tumor cells,this strategy has entered a new phase of clinical practice.Nevertheless,CAR-T cell therapy has not yet achieved the expected results in the treatment of solid tumors,and its potential adverse effects still cause widespread concern.With the continuous advancement of science and technology,multiple cell types modified on the base of CAR technology,such as NK cells,macrophages,NKT cells,andγδT cells,are being included in tumor treatment studies,expanding the therapeutic outlook.This review delves into the latest advances in CAR technology and its application in cell therapy,providing potential new ideas and possibilities for antitumor therapy.

关 键 词：嵌合抗原受体 临床试验 免疫细胞 造血干/祖细胞 诱导性多能干细胞 

分 类 号：R730.51[医药卫生—肿瘤] R318[医药卫生—临床医学]